“The highest R&D spends will always happen in biologics because the highest cost of R&D spend is in clinical trials. As we move forward, there are indications that we can shrink the clinical trials to smaller and smaller cohorts as the regulatory agencies and the markets become more mature in terms of biosimilars. We expect the R&D spends to reduce from current levels.”